Patent ID: 7314863

Claim:
A method of inhibiting angiogenesis which comprises administering to a subject in need thereof an effective amount of a compound of formula (I) wherein X 21 -X 30 are monomeric building blocks, preferably aminocarboxylic acid residues and are derived from a structure in which X 21 =D-Cys, X 22 =Asn, X 23 =Lys, X 24 =Tyr, X 25 =Phe, X 26 =Ser, X 27 =Asn, X 28 =Ile, X 29 =Cys and X 30 =Trp, Y is a spacer and m is 0 or 1, and the monomeric building blocks are linked via —CONR 1 or —NR 1 CO bonds, in which R 1 in each case independently is hydrogen, methyl or ethyl, and pharmaceutically acceptable salts and derivatives thereof, with the proviso that at least one of the amino acid residues X 21 -X 30 is replaced by one of the amino acid residues listed below: X 21 : Asp, Glu, 2,3-diaminopropionic acid (Dap), 2,4-diaminobutyric acid (Dab), D-penicillanine (D-Pen), allylglycine (Alg), ornithine (Orn), Lys; X 22 : Asp, Glu; X 23 : Dab, Dap, His, citrulline (Cit), homocitrulline (Hci), norleucine (Nle); X 24 : homophenylalanine (Hph), 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic), thienylalanine (Thi), Trp, phenylglycin (Phg), 1-naphthylalanine (1-Nal), 2-naphthylalanine (2-Nal), Cha (cyclohexylalanine); X 25 : Trp, Tic, Thi, Hph, Phg; X 26 : Val; X 27 : Asp, Glu; X 28 : Cha, 2-aminobutyric acid (Abu), tert-leucine (Tle), α-aminoisobutyric acid (Aib); and X 29 : Asp, Glu, Dap, Dab, Alg, D-Pen, Orn, Lys, wherein angiogensis is inhibited in cells expressing a urokinase receptor (uPAR).